Abstract
Familial combined hyperlipidemia (FCH) is a primary atherogenic dyslipidemia with insulin resistance and increased cardiovascular risk. Plasminogen activator inhibitor type 1 (PAI-1) and myeloperoxidase (MPO) activity are associated with proinflammatory...
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have